SGLT2 inhibitor users had a lower prevalence of chronic kidney disease, heart failure, and a history of stroke, and they were more likely to have used insulin, metformin, and glucagon-like peptide-1 (GLP1) agonists in the baseline period when compared to DPP4 inhibitor users. The gene discussed is GLP1R; the disease is chronic kidney disease.